Scynexis is recalling two lots of Brexafemme (ibrexafungerp) tablets 150 milligram, 4 count cartons. The antifungal drug is approved for vulvovaginal candidiasis.
The possible cross-contamination risk is with ezetimibe, a non-antibacterial beta-lactam compound that could lead to swelling, rash, hives, anaphylaxis and a life-threatening reaction, according to the FDA. No adverse events have been reported.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
